We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster
News

RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster
News

RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem cell therapies are becoming increasingly important to healthcare advancement around the world. Rising care delivery costs, worldwide population aging, and potential physician shortages are only three of the issues facing world healthcare providers. The cost to bring a new drug to market has soared to $1.3 billion, and there are now half as many drugs seeking approval as there were 15 years ago.

Rising costs and potential shortages have led to a boom in demand for stem cell therapies. These advanced treatments could soon help to ease costs and provide effective disease treatment, potentially improving patient outcomes and reducing health care costs. For that to happen, however, real challenges must be overcome. Translation of these therapies from the lab to the clinic is slow, and widespread implementation could be a decade away or more.

Thanks to n3D’s Bio-Assembler technology, however, the development timeline for many stem cell therapies could potentially be shortened significantly. The Bio-Assembler enables researchers to culture cells in three dimensions faster and more easily than ever before, streamlining testing and research.

On Thursday, RBCC announced the acquisition of an equity interest in n3D, a fully commercialized company with plans to sell the ground-breaking Bio-Assembler to labs and researchers all over the world. RBCC expects n3D’s value to grow considerably as word spreads about the game-changing technology.

Advertisement